Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VYGR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVoyager Therapeutics receives FDA clearance to begin Alzheimer's gene therapy trial
Filed June 1, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
high
FDA cleared IND application for VY1706, an investigational gene therapy targeting tau protein in Alzheimer's disease, allowing human clinical trials to proceed
Item 8.01 verify on EDGAR → -
high
Company plans to begin dosing patients in second half of 2026 in multi-site Phase 1 trial, providing near-term clinical milestone
Item 8.01 verify on EDGAR → -
medium
Trial will enroll up to 18 early Alzheimer's patients across three dose cohorts, with primary focus on safety and secondary endpoints measuring tau biomarkers and brain imaging
Item 8.01 verify on EDGAR →
Summary
Voyager Therapeutics announced FDA clearance to begin human testing of VY1706, a one-time gene therapy designed to silence tau protein in Alzheimer's patients. This regulatory green light represents a significant milestone for the clinical-stage biotech, moving its lead Alzheimer's program from preclinical development into human trials.
The therapy targets both intracellular and extracellular tau, a protein that forms toxic tangles in the brains of Alzheimer's patients. For retail investors, this matters because it validates Voyager's scientific approach and opens the door to potential value creation if the therapy proves safe and effective.
The planned Phase 1 trial will test the therapy in 18 patients with early-stage disease, focusing primarily on safety while also measuring biological effects on tau levels. Dosing is expected to start in the second half of 2026, giving investors a concrete near-term catalyst to monitor. Watch for the company's announcement of first patient dosed, which will mark actual trial initiation. Safety data from the initial dose cohorts will be critical in determining whether VY1706 can advance to larger efficacy studies and potentially compete in the crowded Alzheimer's treatment landscape.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company plans to initiate a multi-site, open-label, dose-escalation clinical trial of VY1706, which is expected to begin dosing in the second half of 2026.
Voyager plans to start dosing patients in a Phase 1 clinical trial during the second half of 2026. This represents a near-term clinical milestone that investors can track. The trial will be conducted at multiple sites and will test escalating doses to establish safety.
Added in current filing · verify on EDGAR →
In the clinical trial, VY1706 will be administered as a one-time, intravenous dose to adult participants with early AD who have evidence of tau pathology in the brain as confirmed by positron emission tomography (“PET”) imaging. The study is expected to enroll up to an aggregate of 18 patients across three cohorts, with the highest dose not exceeding 5 x 1013 vector genomes per kilogram, the highest dose tested in non-human primates in the good laboratory practice toxicology study. The primary endpoint of the study is to evaluate the safety and tolerability of VY1706. Secondary endpoints are designed to assess VY1706’s effect on tau biology, including changes in cerebrospinal fluid biomarkers of tau, as well as changes in tau pathology measured by tau PET imaging.
The trial will enroll up to 18 early Alzheimer's patients across three dose cohorts, with VY1706 given as a single IV infusion. The primary goal is safety assessment, while secondary endpoints will measure biological effects on tau protein through spinal fluid biomarkers and brain imaging. The maximum dose is capped at levels already tested safely in primates.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify